AMR Action Fund
Overview
The AMR Action Fund enables breakthroughs in antimicrobials. It invests in companies that are developing urgently needed therapeutics for priority pathogens and advocates for market reforms to change how society values these lifesaving drugs. The fund's aim is to help launch two to four new antimicrobials within the next decade and create a sustainable ecosystem of investment and innovation to take on one of the biggest global health challenges .
Investments
| Company | Date | Stage | Lead |
|---|---|---|---|
| Trellis Bioscience | Jul 2026 | Series C | Co-investor |
| Telum Therapeutics | Jul 2026 | Series A | Lead |
| Centauri Therapeutics Limited | Feb 2026 | Series A Extension | Lead |
| Pattern BioSciences | Nov 2025 | Series D | Lead |
| Pattern Bioscience | Nov 2025 | Series D | Lead |
Sector & Stage Mix
Industry, funding stage, and valuation band breakdowns.
